Administration of G-CSF can be delayed after transplantation of autologous G-CSF-primed blood stem cells: A randomized study

Bone Marrow Transplantation

Volumn 17, Issue 4, 1996, Pages 533-536

  Faucher, C ^a   Le Corroller, A G ^b   Chabannon, C ^a   Novakovitch, G ^a   Manonni, P ^a   Moatti, J P ^a,b   Nouyrigat, P ^a   Maraninchi, D ^a   Blaise, D ^a  

^a INSTITUT PAOLI CALMETTES   (France)

^b INSERM   (France)

Author keywords

Blood stem cells; Cost; Delayed G CSF

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADOLESCENT; ADULT; ANTIBIOTIC THERAPY; APHERESIS; ARTICLE; AUTOTRANSPLANTATION; BREAST CANCER; CELL TRANSPLANTATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST; DRUG EFFECT; FEMALE; HEMATOPOIETIC STEM CELL; HODGKIN DISEASE; HOSPITALIZATION; HUMAN; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOLID TUMOR; STEM CELL TRANSPLANTATION; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTE COUNT;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD TRANSFUSION; BONE MARROW; CELL MOVEMENT; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRAFT SURVIVAL; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; NEOPLASMS; PLATELET COUNT; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 0029991273     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Sheridan WP, Morstyn G, Wolf M et al. Granulocyte colony-stimulating factor and neutrophil recovery after high-dose chemotherapy and autologous bone marrow transplantation. Lancet 1989; 2: 891-895.
2. Gisselbrecht C, Prentice HG, Bacigalupo A et al. Placebo-controlled phase III trial of lenograstim in bone marrow transplantation. Lancet 1994; 343; 696-700.
3. Nemunaitis J, Rabinowe SN, Singer JW et al. Recombinant granulocyte macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. New Engl J Med 1991; 324: 1773-1777.
4. Vey N, Molnar S, Faucher C et al. Delayed administration of granulocyte colony-stimulating factor after autologous bone marrow transplantation: effect on granulocyte recovery. Bone Marrow Transplant 1994; 14: 779-782.
5. Besinger W, Singer J, Appelbaum F et al. Autologous transplantation with peripheral blood mononuclear cells collected after administration of recombinant granulocyte stimulating factor. Blood 1993: 81: 3158-3163.
6. Gianni AL, Siena S, Bregni M et al. Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation. Lancet 1989: 9: 580-584.
7. Williams SF, Bitran JD, Richards JM et al. Peripheral blood derived stem cell collections for use in autologous transplantation after high-dose chemotherapy: an alternative approach. Bone Marrow Transplant 1990; 5: 129-134.
8. Sheridan WP, Begley GC, Juttner CA et al. Effect of peripheral blood progenitor cells mobilized by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 1992; 339: 640-644.
9. Chao NJ, Schriber JR, Grimes K et al. Granulocyte colony-stimulating factor 'mobilized' peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy. Blood 1993; 81: 2031-2035.
10. Faucher C, Le Corroller AG, Biaise D et al. Comparison of G-CSF primed peripheral blood progenitor cells and bone marrow autotransplantation: clinical assessment and cost-effectiveness. Bone Marrow Transplant 1994; 14: 895-901.
11. - hematopoietic stem cells in the peripheral blood of high-dose cyclophosphamide-treated patients: enhancement by intravenous recombinant human granulocyte-colony stimulating factor. Blood 1989; 74: 1905-1914.
12. Peters P, Rosner G, Ross M et al. Comparative effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte-colony stimulating factor (GM-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. Blood 1993; 81: 1709-1719.
13. Gaspard MH, Maraninchi D, Stoppa AM et al. Intensive chemotherapy with high-dose of BCNU, etoposide, cytosine arabinoside and melphalan (BEAM) followed by autologous BMT: toxiciry and antitumor activity in 26 patients with poor risk malignancies. Cancer Chem Pharm 1988; 22: 256-262.
14. Gisselbrecht C, Devaux Y, Lotz JP et al. Autologous bone marrow transplantation (ABMT) after high-dose cyclophosphamide, mitoxantrone, alkeran (CMA) in breast cancer. AACR. 82nd Annual Meeting, Houston, May 19-21, 1991, (abstr. 4674).
15. To LB, Roberts MM, Haylock DN el al. Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cells transplant, autologous bone marrow transplants and allogeneic bone marrow transplants. Bone Marrow Transplant 1992; 9: 277-284.
16. Spitzer G, Adkins DR, Spencer V et al. Randomized study of growth factors post-peripheral blood stem-cells transplant: neutrophil recovery is improved with modest clinical benefit. J Clin Oncol 1994; 12: 661-670.
17. Klumpp TR, Mangan KF, Goldberg SL et al. Granulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation: a prospective, randomized trial. J Clin Oncol 1995; 13: 1323-1327.